292 related articles for article (PubMed ID: 16251289)
1. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys.
Ajariyakhajorn C; Mammen MP; Endy TP; Gettayacamin M; Nisalak A; Nimmannitya S; Libraty DH
Antimicrob Agents Chemother; 2005 Nov; 49(11):4508-14. PubMed ID: 16251289
[TBL] [Abstract][Full Text] [Related]
2. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand.
Endy TP; Nisalak A; Chunsuttitwat S; Vaughn DW; Green S; Ennis FA; Rothman AL; Libraty DH
J Infect Dis; 2004 Mar; 189(6):990-1000. PubMed ID: 14999601
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques.
Asmuth DM; Abel K; George MD; Dandekar S; Pollard RB; Miller CJ
J Med Primatol; 2008 Feb; 37(1):26-30. PubMed ID: 18199069
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha.
Morrill JC; Jennings GB; Cosgriff TM; Gibbs PH; Peters CJ
Rev Infect Dis; 1989; 11 Suppl 4():S815-25. PubMed ID: 2546250
[TBL] [Abstract][Full Text] [Related]
8. Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys.
Lin HH; Lee HC; Li XF; Tsai MJ; Hsiao HJ; Peng JG; Sue SC; Qin CF; Wu SC
PLoS One; 2014; 9(6):e100130. PubMed ID: 24959738
[TBL] [Abstract][Full Text] [Related]
9. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.
Laoprasopwattana K; Libraty DH; Endy TP; Nisalak A; Chunsuttiwat S; Vaughn DW; Reed G; Ennis FA; Rothman AL; Green S
J Infect Dis; 2005 Aug; 192(3):510-9. PubMed ID: 15995967
[TBL] [Abstract][Full Text] [Related]
10. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication.
Laoprasopwattana K; Libraty DH; Endy TP; Nisalak A; Chunsuttiwat S; Ennis FA; Rothman AL; Green S
J Infect Dis; 2007 Apr; 195(8):1108-16. PubMed ID: 17357046
[TBL] [Abstract][Full Text] [Related]
13. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.
Galler R; Marchevsky RS; Caride E; Almeida LF; Yamamura AM; Jabor AV; Motta MC; Bonaldo MC; Coutinho ES; Freire MS
Braz J Med Biol Res; 2005 Dec; 38(12):1835-46. PubMed ID: 16302098
[TBL] [Abstract][Full Text] [Related]
14. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
[TBL] [Abstract][Full Text] [Related]
15. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.
Jessner W; Stauber R; Hackl F; Datz C; Watkins-Riedel T; Hofer H; Gangl A; Kessler H; Ferenci P
J Viral Hepat; 2003 Jan; 10(1):37-42. PubMed ID: 12558910
[TBL] [Abstract][Full Text] [Related]
16. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.
Schul W; Liu W; Xu HY; Flamand M; Vasudevan SG
J Infect Dis; 2007 Mar; 195(5):665-74. PubMed ID: 17262707
[TBL] [Abstract][Full Text] [Related]
17. A blunted blood plasmacytoid dendritic cell response to an acute systemic viral infection is associated with increased disease severity.
Pichyangkul S; Endy TP; Kalayanarooj S; Nisalak A; Yongvanitchit K; Green S; Rothman AL; Ennis FA; Libraty DH
J Immunol; 2003 Nov; 171(10):5571-8. PubMed ID: 14607965
[TBL] [Abstract][Full Text] [Related]
18. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
Leuk Lymphoma; 2007 Mar; 48(3):497-505. PubMed ID: 17454589
[TBL] [Abstract][Full Text] [Related]
19. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis.
Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L
J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006
[TBL] [Abstract][Full Text] [Related]
20. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
